Screening for primary hyperaldosteronism (PHA) is often indicated in individuals with resistant hypertension or hypokalaemia. However, in the far larger subset of the hypertensive population who do not fit into these criteria, the evidence for screening is conflicting and dependent on the disease prevalence. The purpose of this study was to examine the prevalence of PHA in a large population with mild to moderate hypertension and without hypokalaemia using a carefully controlled study protocol including a normotensive control population. Hypertensive subjects underwent medication washout and both hypertensive and normotensive subjects placed on a high-sodium diet prior to biochemical and haemodynamic testing. Study specific cutoff values were based on results from the normotensive population studied under identical conditions. A screening test (serum aldosterone/PRA ratio [ARR]425 with a serum aldosterone level 48 ng/dl) was followed by a confirmatory test (urine aldosterone excretion rate [AER] 417 lg/ 24 h) to demonstrate evidence of PHA. An elevated ARR with a concomitant elevated serum aldosterone was present in 26 (7.5%) individuals. Of these, 11 (3.2%) had an elevated AER, consistent with evidence of PHA. Individuals with PHA had higher blood pressure and lower serum potassium levels while on a high-sodium diet. Sodium restriction neutralized these differences between PHA and essential hypertensives. The prevalence of PHA in this mild to moderate hypertensive population without hypokalaemia is at most 3.2%, a rate that might lead to excessive false positives with random screening in comparable populations. Hyperaldosteronism, when present, is responsive to sodium restriction.
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Introduction
Since Dr Conn's initial description of autonomous aldosterone secretion leading to high blood pressure and hypokalaemia, 1 primary hyperaldosteronism (PHA) has been a well-known cause of secondary hypertension. 2 Furthermore, although the classical description was that of surgically remedial adenomatous tumor formation it is now realized that apparent aldosterone hypersecretion more often than not is the result of 'bilateral adrenal hyperplasia' or even essential hypertension. 3, 4 Recently, considerable controversy [5] [6] [7] [8] has arisen regarding the prevalence of PHA in the mild to moderate hypertensive population who comprise 90% of hypertensives and are largely cared for by primary care providers. 9 Most experts agree that relatively higher prevalence rates for PHA in high-risk populations (those with resistant hypertension or hypertension with hypokalaemia) warrant screening for PHA in this small subset of hypertensives. 5, [10] [11] [12] [13] However, reported estimates of PHA in studies of the larger group of patients with normokalaemia and mild to moderate hypertension range from as low as 2% to more than 30%. 11, [13] [14] [15] [16] [17] [18] The larger percentage, if correct, would justify widespread screening for this potentially curable form of hypertension.
Limitations in establishing prevalence rates for this population have been hampered by small sample sizes, sample bias, concomitant use of medications as a confounder (reported by some 19 but not by others 20 ), uncontrolled dietary sodium and potassium intake at time of testing, variations in posture at time of testing and lack of an adequate normotensive control population 5, 19, [21] [22] [23] and consequent reliance on laboratory reference ranges. This variability contributes to a considerably high falsepositive rate of 6-25% with general application. 24, 25 Determining an accurate prevalence rate for PHA in the non-referral, mild to moderate hypertensive population might have practical significance since a low rate would influence pretest probability and selection for screening. Therefore, the aim of this study was to examine the prevalence of PHA in a diverse population of hypertensive patients without resistant hypertension or hypokalaemia -those with mild to moderate hypertension. We selected and applied practical yet established screening (serum aldosterone to renin ratio) and diagnostic (urine aldosterone excretion rate (AER) on a high-sodium diet) tests for our analysis. Assessment of the reninangiotensin-aldosterone axis occurred under controlled dietary conditions in a General Clinical Research Center (GCRC) after withdrawal of antihypertensive medication. Comparisons were made to a large normotensive control population studied under identical conditions to derive study specific cutoff values for the screening and diagnostic tests. It should be emphasized that the main purpose of this analysis was to determine the prevalence rate of PHA in general. The cutoff values generated are specific to the strictly controlled conditions described in this study. They are not intended to represent new cutoff values for broad application. Furthermore, due to the study design we were unable to determine the underlying cause for PHA (i.e. adenoma vs hyperplasia). Hence, the prevalence of classical or 'surgically remedial' PHA in our population is far less than what we report in the general PHA cohort.
Materials and methods
Individuals described in this report were studied by the international HyperPath (Hypertensive Pathotype) group using standardized protocols and study conditions with all assays performed in a centralized laboratory. Data were analysed from 118 normotensive and 347 hypertensive volunteers. The institutional review boards of each participating institution approved the study protocol and written informed consent was obtained from each participant.
Study participant selection
Screening history, physical and laboratory data were obtained from each participant prior to enrolment. Normotensive volunteers reported a negative personal and family history of hypertension, cardiovascular, kidney, pulmonary and liver disease. Race and ethnicity were self-defined. Measured blood pressure o130/85 mmHg, normal laboratory testing results from measures of serum electrolytes, creatinine, urinalysis, liver and thyroid function and a normal resting 12-lead EKG were required for normal volunteers to participate in the study.
Hypertensive and normotensive participants were recruited through a number of mechanisms, including mass-mailings, newspaper and posted advertisements, and referral from other study participants. In order to qualify for the study, hypertensive patients were required to have a history of hypertension with a diastolic blood pressure (DBP) X100 mmHg on no medications, DBPX90 mmHg on one antihypertensive agent, or the use of two or more antihypertensive medications at the time of screening. Patients were excluded from participating in the study if they had a diastolic blood pressure 4110 mmHg while on two or more medications, or the presence of hypokalaemia (serum potassium o3.5 mg/dl), and/or those with active cardiac or vascular disease. All patients on converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB) or aldosterone antagonists discontinued these medications 3 months prior to the study because of their known effects on the modulation of renin-angiotensin-aldosterone system (RAAS) function in some hypertensive patients. Those on beta-blockers had their medications discontinued for 3-4 weeks. If needed, patients were placed on either a dihydropyridine calcium channel blocker or thiazide diuretic or both to control blood pressure during the washout period. All medications were discontinued 2-4 weeks prior to the study.
Responsiveness of renin and aldosterone to dietary sodium intake Participants completed a 2-week crossover study consisting of 7 days of high dietary sodium intake (4200 mmol/day) and 7 days of low dietary sodium intake (o10 mmol/day). The duration of each diet period was chosen based on prior evidence demonstrating an average time to sodium homeostasis of approximately 5 days in hypertensive patients. 26 High-sodium diet was accomplished by continuing the individual's usual diet supplemented with 2-3 packets of bullion broth at lunch and dinner (adding approximately 100-150 mmol Na/day). The Dietary Core of each center's General Clinical Research Center (GCRC) prepared all low-sodium meals, drinks and snacks after an intake interview with each participant to estimate usual caloric intake. Each diet was supplemented accordingly to contain approximately 100 mmol/day potassium to control for the independent influence of potassium on aldosterone secretion. 2 Urinary sodium, potassium and AER at the end of each study week were determined from a 24-h collection obtained in a GCRC setting. Urinary creatinine excretion rates were also derived to assess completeness of collections. At the end of each diet period, subjects were admitted to the GCRC for one night and one day during which in the morning (between 0800 and 0900) haemodynamic and hormonal assessments were carried out. In order to reduce confounding from environmental stimuli or posture, all study participants remained fasting and supine for 10 h prior to study measurements including blood pressure and hormonal assessment.
Morning supine blood pressure was recorded during each study by an automatic recording device (Dinamap; Critikon, Tampa, FL, USA) at 5-min intervals and averaged for analysis.
Primary hyperaldosteronism screening and diagnostic tests Although there are several screening tests available for PHA, the most widely used in general practice is the aldosterone/plasma renin activity ratio (ARR). The basis of the ARR as a determinant of autonomous aldosterone secretion stems from the normally direct and dependent relationship between aldosterone and endogenous angiotensin II, the latter being extrapolated from the more readily measured plasma renin activity (PRA). An elevated ratio of serum aldosterone to PRA supports the diagnosis of autonomous aldosterone secretion regardless of sodium intake. 16 To increase specificity, we and others 5, 7 required that an elevated ARR be accompanied by an elevated aldosterone concentration to avert falsely high ratios merely from very low PRA values. Patients with elevated ARR were then analysed for the presence of elevated urine aldosterone excretion while on the high-sodium diet to confirm biochemical evidence of PHA. 13, 20, 27 Laboratory procedures Details of laboratory procedures have been described previously. 28, 29 In brief, all blood samples were collected on ice and centrifuged immediately and plasma separated and frozen until the time of assay. Urine and serum electrolytes were measured using an ion-selective electrode. PRA, serum aldosterone and urine aldosterone excretion were determined by radioimmunoassay. 30, 31 The lower limit of detection for the PRA assay was 0.10 ng/ml/h.
Statistical analysis
Data are presented as means with s.e.m. as the measure of dispersion. In this multi-center study, homogeneity of parameters including blood pressure assessment was investigated and assured across the four centres before data were pooled and analysed. Probability was assessed by t-test with adjustments for equal and unequal variance when applicable according to Levene's test. Fisher's exact test was applied to comparison of percentages. A two-tailed P-value of o0.05 described statistical significance. Data derived from the normotensive population was used to generate study-specific cutoff values for the presence of PHA in the hypertensive population. The SPSS statistical software package was used for all analyses (SPSS version 12.0, Chicago, IL).
Results
Subject characteristics are presented in Table 1 . Hypertensive patients were slightly older and had higher levels of serum aldosterone and ARR than normotensives. Serum and urine electrolytes and creatinine were similar between the two groups.
Screening for primary aldosteronism with ARR We calculated ARR in the normotensive participants studied on a high-sodium diet. To prevent an elevated ARR from occurring merely due to smaller PRA values in the denominator, we also calculated the 95th percentile for serum aldosterone (48 ng/dl) and required this to be present for the ARR to be considered elevated. The 95th percentile for ARR in normotensive participants was 25.
In the hypertensive patients, 68 individuals (20%) had an ARR425 yet only 26 (7.5%) remained after requiring a serum aldosterone 48 ng/dl (Figure 1 ). This was considered a 'positive ARR screen' for PHA. All individuals with ARR425 but serum aldosterone o8 ng/dl had PRA values p0.2 ng/ml/ h, thus demonstrating the limitations of relying solely on the calculated ARR without requiring an elevated serum aldosterone level as a screening criterion. Table 2 compares characteristics of subjects with a positive and negative ARR screening test. Besides obvious differences in aldosterone and PRA, serum potassium concentrations were significantly lower (albeit in the normal range) and blood pressure was higher in the positive ARR screen group.
Determination of urine AER under high-sodium conditions
The second phase of analysis determined urine AER on a high sodium (urine sodium excretion, 22477 mmol/24 h) and controlled potassium (urine potassium excretion, 7472 mmol/24 h) diet. To minimize false-negative cases in this phase of the study, we used the 90th percentile value for AER in the normotensive population (17 mg/24 h) to designate cases of PHA. Of the 26 patients with an elevated ARR, 11 (3.2% of the hypertensive patients) had PHA as determined by an elevated AER. Using a more conservative 95th percentile value for AER (20 mg/24 h), the number of patients with an elevated value was eight (2.3%). In the 11 PHA patients, all had suppressed PRA levels (o0.50 ng/ ml/h). Comparisons of patients with PHA and the remaining hypertensive patients revealed significantly higher blood pressure and lower serum potassium concentrations (although still in the normal range) in those with PHA (Table 3) .
Responsiveness to dietary sodium restriction
We studied the RAAS and blood pressure responsiveness to sodium restriction and upright posture in the hypertensive patients to assess the degree of volume expansion and aldosterone excess in patients with PHA. The low-sodium diet followed by 90 min upright posture produced significant responses in PRA, aldosterone and blood pressure in both PHA and hypertensive patients. Comparisons of low sodium/upright posture values between groups revealed no significant differences in aldosterone, blood pressure, or potassium (Table 4) despite baseline differences in these parameters on a high-sodium diet. Only PRA remained significantly suppressed in the PHA patients. Thus, sodium restriction and upright posture neutralized most of the differences between patients with PHA and the remaining hypertensive patients, and produced a profound drop in blood pressure in patients with PHA. Characterization of the 11 patients with PHA is provided in Table 5 .
Discussion
Prevalence rates play a critical role in determining the appropriate application of screening tests.
Screening for a disease with a low prevalence leads to excessive false positives. With regard to PHA, there is consensus that patients with resistant hypertension or hypertension with hypokalaemia should be screened for PHA. 5, [10] [11] [12] [13] Less clear, yet of possibly greater concern, is whether to screen the majority of patients who do not have these classical signs or symptoms -those with mild to moderate hypertension and normokalaemia. This group comprises 80-90% of the general hypertensive popula- tion that are cared for in the primary care settings. 9 The purpose of this study was to determine the prevalence of PHA in a population of hypertensives who may not typically be considered as candidates for screening. In this analysis of a diverse yet strictly controlled group of hypertensive patients, we found the prevalence of PHA to be 3.2%. Since we were unable to determine the underlying cause for aldosterone hypersecretion (i.e. adenoma vs hyperplasia), the prevalence of classical or 'surgically remedial' PHA in our population is likely far less than 3.2%. It should be emphasized that the aim of this study was not to advocate new diagnostic cutoff values or criteria. The strictly controlled study environment outlined in this report would be impractical to duplicate and as mentioned previously invariably leads to different cutoff values than those typically reported. For this reason, we provided normal control data to generate cutoff criteria.
We chose widely accepted screening and diagnostic tests to demonstrate biochemical evidence of PHA. It should be pointed out that all study participants (normotensive and hypertensive) were studied on a high-sodium diet with potassium supplementation. This resulted in laboratory values that may appear different than are reported by some reference laboratories (typically obtained during random sodium and potassium intake). However, this also allowed us to derive cutoff values from the normotensive participants studied under identical conditions. Our ARR value of 25 is similar to that of several prior reports. Our AER of 17 mg/24 h is somewhat higher than the value of 12-14 mg/24 h typically reported. [32] [33] [34] [35] This is likely due to controlled potassium supplementation (total potassium intake, 100 mmol/day) in both normotensive and hypertensive populations as evidenced by higher than typical, but equivalent, urine potassium excretion rates of about 70 mmol/day (with unmeasured colonic excretion comprising the difference in intake 36 ) and consequent potassium-mediated stimulation of aldosterone. Incidentally, an AER cutoff value of 14 mg/day (75th percentile) would raise the number of cases of PHA slightly to 15.
A comparison of individuals with PHA vs those without PHA showed significantly lower serum potassium levels and higher blood pressure at both the screening and diagnostic phases of the study. While those with PHA had significantly lower serum potassium levels, as part of the study design none had values below the lower limit of the normal range at time of entry. We found no difference in age between those with or without PHA, as has been reported by others. 32, 37 We found that a low-sodium diet with upright posture led to a significant increase in PRA and serum aldosterone even in the PHA group. Interestingly, although PRA was relatively hyporesponsive in PHA patients after sodium restriction when compared to the response in those without PHA, blood pressure, serum potassium, and aldosterone (urine and serum) were not different between groups. This suggests that while PHA is uncommon in mild to moderate hypertensive patients represented by this study cohort its clinical manifestations were abrogated by dietary sodium restriction, albeit to very low levels (10 mmol/day).
Reported prevalence rates of PHA range from 2-30%, with a tendency for higher rates to be reported subsequent to more widespread use of ARR in screening. 11, [13] [14] [15] [16] [17] [18] Higher prevalence rates also appear in series from hypertension referral centers, likely due to inherent selection bias (e.g. severe and/or resistant hypertension). Mulatero 18 described a multi-national registry advocating widespread use of the ARR in screening for PHA. However, their analysis was performed retrospectively with different laboratory normal values, no normal control group, and was based on a hypertension referral center patient population. Fardella 21 described a 10% prevalence rate for PHA among patients recruited from a hypertension referral center. Mosso 37 similarly reported prevalence rates of up to 8% in a general hypertensive population. Rossi 38 reported a prevalence of PHA at 6.3%, but positive results were based on comparisons to normal laboratory reference ranges and not derived from a control group studied under identical conditions.
The strengths of our findings include a strictly controlled study protocol, a large group of similarly studied normal individuals, and broad multinational and cultural heterogeneity. We also employed a lengthy wash-out period for medications known to influence RAAS activity 27,39-41 whether or not they are felt to influence the interpretation of screening or diagnostic tests. 19, 20 Limitations of this study include shortcomings inherent to a secondary analysis of a data set. Also, we did not have the ability to comment on specific adrenal pathology (e.g. aldosterone producing adenomas or hyperplasia) although it should be realized that these procedures are conducted to determine the etiology of inappropriate aldosterone secretion only after first establishing biochemical evidence of autonomous aldosterone secretion such as demonstrated in this study. Some have advocated qualifying an elevated ARR to include either an elevated aldosterone concentration and/or a fixed, minimum PRA level in order to avoid false positives generated solely from low PRA values. 5 In this study, we imposed an elevated serum aldosterone concentration based on results from the normotensive subjects before considering results from the diagnostic test.
Had we also applied an absolute PRA cutoff value (0.4 ng/ml/h) the prevalence rate for PHA would have been reduced to 2.5%.
The higher sodium content (approximately 220 mmol/day) and longer duration of dietary sodium intake (7 days) described in this study diet could have led to greater suppression of RAAS activity and thereby influenced our analyses. While the sodium content of most Western diets is in the 140-180 mmol/day range, 42 this intake lies on the upper, flat portion of the dose-response curve for RAAS activity. 43 The 7-day diet period was chosen based on prior evidence demonstrating an average time to sodium homeostasis of approximately 5 days in hypertensive patients. 26 Thus, the longer duration and higher sodium intake would actually reduce the frequency of false positives due to delayed suppression of urine aldosterone excretion, which might have appeared with a shorter period and/or lesser sodium intake.
The findings of sodium responsiveness were under conditions of extreme sodium restriction and therefore not clinically practical to advocate. However, defining a dose-response relationship between sodium intake and haemodynamic and hormonal factor might warrant investigation to determine the potency of sodium restriction in the treatment of PHA.
In summary (Table 6) , we found that the prevalence of PHA in a population with mild to moderate hypertension without hypokalaemia was at most 3.2%. Among those with PHA, most of the clinical manifestations were neutralized by dietary sodium restriction. A low prevalence rate might influence screening behaviours in this population. Table 6 Summary of current literature and contributions from this study What is known on this subject K Primary hyperaldosteronism (PHA) is a treatable and potentially reversible form of secondary hypertension. 2, [5] [6] [7] [10] [11] [12] [13] 27 K Screening for PHA is established in high-risk populations (patients with resistant hypertension or hypertension with hypokalaemia) 5,10-13 but is conflicting in nonreferral populations. 11, 13, [15] [16] [17] [18] K Biochemical evidence of PHA is necessary before investigating the etiology of inappropriate aldosterone production. 2, 5, 13, 23 K Clinical conditions at time of testing can obscure both the screening and diagnosis of PHA and therefore influence the prevalence rate. 5, [19] [20] [21] [22] [23] [24] [25] What this study contributes K After controlling for several known confounders including dietary sodium and potassium, posture, medication, circadian rhythms and using a normotensive control population we found the prevalence of PHA in the majority of essential hypertensives (those with mild to moderate hypertension without hypokalaemia) to be 3.2%. K At a prevalence of 3.2%, screening for PHA in this population might lead to a high false-positive rate. K The cutoff values described herein are study specific and not meant to establish new guideline values. K Hyperaldosteronism when present in this population is responsive to dietary sodium restriction.
